Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Can amylin weight loss drugs compete in a world of GLP 1s? C&EN Global Enterprise Long acting amylin related peptides as therapies for obesity and type 2 diabetes ScienceDirect CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension